MEC Plus Full List ViewBy pinki@katapult.biz / February 16, 2025 MEC Plus Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignant Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Oral Cancer Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title Type of Media — Video Document Audio Events — 2024 California Cancer Consortium Conference (CCC) 2024 MCM 2024 MCM 2024 MLS Cleveland 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 WCS 2024 MaTOS Lungs 2025 PRIMO Search Everything « 1 … 19 20 21 22 23 … 96 » Pan-KRAS Inhibitors: Where are We Going? Ferdinandos Skoulidis, MD View Video Overcoming T-Cell Exhaustion Brian S. Henick, MD View Video Optimal Surgical Approach for Mesothelioma Raja Flores, MD View Video Optimal Management of Limited Stage SCLC Paul Bunn, MD View Video Optimal Management of Extensive SCLC (1st and 2nd Line) Charles Rudin, MD, PhD View Video NRG1 as Target in NSCLC? Natasha Leighl, MD View Video Novel Therapies for Thymic Malignancies Jonathan Riess, MD View Video Neoadjuvant Immunotherapy Position Marina Garassino, MD View Video MRD to Decide Perioperative Management in the Era of Immuno-Oncology Fred Hirsch, MD View Video Minimal Residual Disease (MRD) as Detected by Liquid Biopsy: Where are We Going? Natasha Leighl, MD View Video Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection Hatim Husain, MD View Video Mechanisms of Resistance to ALK Inhibitors Jessica Lin, MD View Video Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC Luis E. Raez, MD View Video KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors Karen Reckamp, MD View Video KRAS mutant NSCLC: What is the Standard of Care Now? Mary Jo Fidler, MD View Video How to Start a Lung Cancer Screening Program Karen Kelly, MD View Video How to Rescue Patients from Osimertinib Resistance Wade T. Iams, MD, MSCI View Video How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps? Mark Kris, MD View Video HER-3 as a New Target in NSCLC Edgardo S. Santos, MD View Video Health Care Disparities in Lung Cancer Genomic Profiling Estelamari Rodriguez, MD View Video Future Challenges for Immunotherapy in the Fight Against NSCLC Hossein Borghaei, DO View Video Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy? Jyoti Patel, MD View Video Exon 20 and Uncommon EGFR Sensitive Mutations John Heymach, MD View Video Developing New Anti-CTL4s for NSCLC: Is There Any Role? Millie Das, MD View Video CAR-T Cell in NSCLC: Is it Feasible? Sally Lau, MD View Video Building the Case for HER-2 Inhibitors in NSCLC Corey Langer, MD View Video Brain Radiotherapy in SCLC: When? Jeffrey Bradley, MD View Video Biomarkers for Perioperative Immunotherapy? David Carbone, MD View Video Best Surgical Approaches for Stage III NSCLC Jay M. Lee, MD View Video Best Approaches for First Line EGFR Mutant NSCLC Joshua Sabari, MD View Video Post navigation ← Previous View We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
